HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc

TRAX

0.00

HC Wainwright & Co. analyst Emily Bodnar maintains First Tracks (NASDAQ: TRAX) with a Buy and raises the price target from $44 to $57.